Dapagliflozin (Farxiga) in Women 65 and Older: What You Need to Know

What Is Dapagliflozin and Why Do Older Women Take It?

Dapagliflozin belongs to the sodium-glucose cotransporter-2 (SGLT2) inhibitor class. It works by blocking glucose reabsorption in the proximal tubule of the kidney, causing excess glucose and a small amount of sodium to be excreted in urine. The result: lower blood sugar, modest weight loss, lower blood pressure, and reduced kidney filtration pressure.

For women 65 and older, the drug is prescribed for three FDA-approved indications: type 2 diabetes (to improve glycemic control and reduce cardiovascular events), heart failure (HFrEF and HFpEF), and chronic kidney disease (CKD). Because cardiovascular disease is the leading cause of death in American women and CKD affects women disproportionately after menopause, these approvals matter enormously for this age group.

How the Postmenopausal Body Changes the Drug's Effect

After menopause, estrogen decline reshapes your metabolic and kidney physiology in ways that affect how dapagliflozin works. Lower estrogen levels are associated with increased visceral adiposity, insulin resistance, and a shift toward a more atherogenic lipid profile. SGLT2 inhibitors address several of these simultaneously: they reduce body weight by roughly 2 to 3 kg on average, lower systolic blood pressure by approximately 3 to 5 mmHg, and reduce HbA1c by 0.5 to 1.0 percentage points in older adults.

Postmenopausal women also have a naturally lower glomerular filtration rate trajectory than premenopausal women. Data from the DAPA-CKD trial showed that dapagliflozin reduced the risk of a sustained decline of 50% or more in eGFR, end-stage kidney disease, or kidney or cardiovascular death by 39% compared with placebo across the full study population, with consistent effects across sexes and age subgroups.

The Glycosuria Mechanism and Older Women

The drug works by excreting roughly 70 grams of glucose per day in urine at standard doses. That glucose-rich urine creates a warm, nutrient-rich environment in the lower genital tract, which is why vulvovaginal candidiasis rates are higher with SGLT2 inhibitors than with placebo. After menopause, the vaginal epithelium is thinner, glycogen-depleted, and less acidic, making it even more susceptible to yeast overgrowth. This is not a reason to avoid the drug, but it is a reason to counsel older women proactively.

On-Label Uses for Women 65 and Older

Type 2 Diabetes

Dapagliflozin is approved as an adjunct to diet and exercise in adults with type 2 diabetes. In the DECLARE-TIMI 58 trial, which enrolled more than 17,000 patients across a broad glycemic spectrum, dapagliflozin reduced the rate of hospitalization for heart failure or cardiovascular death versus placebo, with consistent findings in participants over 65. For older women already on metformin or insulin, adding dapagliflozin at 10 mg daily provides glycemic benefit with a low intrinsic hypoglycemia risk (it does not stimulate insulin secretion).

Glycemic targets in women over 65 are often individualized. The American Diabetes Association's Standards of Care recommend less stringent HbA1c targets (7.5 to 8.0%) for older adults with multiple comorbidities or limited life expectancy, and dapagliflozin's modest HbA1c-lowering fits well within that frame.

Heart Failure

The DAPA-HF trial enrolled patients with HFrEF (ejection fraction 40% or less) and found that dapagliflozin 10 mg daily reduced the composite of worsening heart failure or cardiovascular death by 26% versus placebo. The DELIVER trial then extended this benefit to HFpEF (ejection fraction above 40%), which is the dominant heart failure phenotype in older women. In DELIVER, dapagliflozin reduced worsening heart failure events or cardiovascular death by 18% versus placebo. Women represented about 44% of the DELIVER cohort, and sex-specific subgroup analyses showed consistent benefit.

Chronic Kidney Disease

Dapagliflozin received FDA approval for CKD in adults regardless of diabetes status in 2021, based on DAPA-CKD. The trial required baseline eGFR of 25 to 75 mL/min/1.73 m² and urine albumin-to-creatinine ratio of 200 to 5,000 mg/g. Women over 65 with diabetic nephropathy or IgA nephropathy (both enrolled in DAPA-CKD) are appropriate candidates. The trial was stopped early for overwhelming efficacy: the primary endpoint was reduced by 39% with dapagliflozin.

Off-Label Uses Being Explored in Older Women

Dapagliflozin is being studied or used off-label in several conditions particularly relevant to older women. The evidence base varies considerably by indication.

Metabolic Dysfunction-Associated Steatohepatitis (MASH)

MASH (formerly NASH) is more prevalent in women after menopause due to estrogen loss and visceral fat accumulation. Small trials suggest SGLT2 inhibitors may reduce liver fat and inflammation. A meta-analysis of randomized trials published in Hepatology International found SGLT2 inhibitors significantly reduced liver enzymes and steatosis scores, though none of these trials enrolled primarily postmenopausal women, so the evidence is extrapolated rather than directly established. This is an evidence gap worth naming.

Adjunct Weight Management

The modest weight loss with dapagliflozin (2 to 3 kg) is not sufficient as a primary obesity treatment, but some clinicians use it as a metabolic adjunct alongside GLP-1 receptor agonists in women 65 and older with obesity and cardiovascular disease. There are no large randomized trials specifically examining this combination in older women. Caution is warranted because combined volume depletion from both drug classes may increase fall and fracture risk.

Type 1 Diabetes (Investigational)

Dapagliflozin is not FDA-approved for type 1 diabetes due to diabetic ketoacidosis (DKA) risk. A small subset of older women live with long-standing type 1 diabetes and may encounter off-label use discussions. The FDA issued a warning about increased DKA risk with SGLT2 inhibitors in type 1 diabetes. If your provider raises this, understand that it is not approved, and DKA can present atypically with normal or near-normal glucose in older adults.

Risks and Side Effects Specific to Older Women

The risk profile of dapagliflozin shifts meaningfully after 65. Here is a practical framework for thinking about the four most clinically relevant risks in older women.

Genital and Urinary Tract Infections

Vulvovaginal candidiasis occurs in roughly 8 to 15% of women taking SGLT2 inhibitors versus 2 to 4% with placebo. After menopause, genitourinary syndrome of menopause (GSM) already disrupts vaginal flora and epithelial integrity, amplifying this risk. Urinary tract infections are also more common in postmenopausal women at baseline. Dapagliflozin does not dramatically worsen UTI rates in clinical trials, but Fournier's gangrene (necrotizing fasciitis of the genitalia) is a rare but serious FDA-flagged risk; any perineal pain, swelling, or fever in a woman taking this drug requires urgent evaluation.

Preventive strategies include meticulous genital hygiene, treating concurrent GSM (vaginal estrogen does not interact with dapagliflozin pharmacokinetically), and prompt antifungal treatment at first sign of symptoms.

Volume Depletion, Orthostasis, and Falls

Dapagliflozin has a modest osmotic diuretic effect. In women 65 and older, particularly those already on thiazide diuretics, ACE inhibitors, or ARBs, this can cause symptomatic hypotension and dizziness. Falls in this population are a serious concern. The DAPA-HF investigators reported volume depletion events in approximately 7% of the dapagliflozin arm versus 6% with placebo, a difference that is small in trials but meaningful for frail women. Clinicians often reduce loop diuretic doses by 25 to 50% when initiating dapagliflozin in older women with heart failure.

Bone Health and Fracture Risk

Postmenopausal women already lose bone at an accelerated rate. SGLT2 inhibitors increase phosphate reabsorption and may modestly raise parathyroid hormone, which over time could affect bone turnover. The canagliflozin CANVAS program raised concern about fracture risk, though dapagliflozin-specific data from DECLARE-TIMI 58 did not show a statistically significant increase in fracture rates. The difference between these drugs in bone outcomes may relate to off-target effects of canagliflozin on NHE3. Still, for a woman with osteopenia or osteoporosis, documenting baseline DEXA status and ensuring adequate calcium and vitamin D intake before starting dapagliflozin is prudent clinical practice.

Diabetic Ketoacidosis

DKA with SGLT2 inhibitors is rare in type 2 diabetes but risk rises in older women who fast before procedures, have significant illness, or have reduced caloric intake. Euglycemic DKA can be missed because glucose appears normal. The FDA recommends holding dapagliflozin at least 3 days before elective surgery. Older women with multiple planned procedures need a clear sick-day rule: stop the drug when you are not eating normally, and restart only when eating resumes.

Pregnancy, Lactation, and Contraception

Most women 65 and older are postmenopausal and not at risk for pregnancy. However, perimenopause can extend into the early 60s, and some women in this age range may still ovulate sporadically.

Dapagliflozin is contraindicated during the second and third trimesters of pregnancy based on animal studies showing kidney dysgenesis and reduced fetal body weight when SGLT2 inhibitors are administered during organogenesis and fetal development. Human data in pregnancy are insufficient. The FDA labeling states that exposure during the second and third trimesters may cause fetal renal toxicity, oligohydramnios, and neonatal renal impairment.

For a woman in early perimenopause (late 50s to early 60s) who has not had twelve consecutive months without a menstrual period, reliable contraception should be in place. Dapagliflozin does not appear to interact with hormonal contraceptives pharmacokinetically, but the clinical recommendation is straightforward: if pregnancy is possible, use effective contraception and discuss the risk-benefit ratio with your prescriber.

Lactation data are absent in humans. Animal studies show dapagliflozin is secreted in rat milk, and developing kidneys may be sensitive to SGLT2 inhibition. The FDA labeling advises against breastfeeding while taking dapagliflozin. This is not a practical concern for most women 65 and older but is documented here for completeness and for any perimenopausal woman in her early 60s who is still nursing an infant (a rare but possible clinical scenario).

Who This Drug Is Right For and Who Should Use Caution

Good candidates among older women

Older women who are most likely to benefit from dapagliflozin include those with established cardiovascular disease or high cardiovascular risk and type 2 diabetes, women with heart failure (both HFrEF and HFpEF), women with CKD and an eGFR between 25 and 75 mL/min/1.73 m² with significant albuminuria, and postmenopausal women with type 2 diabetes who need glycemic control without hypoglycemia risk. The DAPA-CKD and DAPA-HF trials showed that benefit accrued regardless of diabetes status, which is a clinically significant point for older women whose primary diagnosis may be heart failure or CKD rather than diabetes.

Women who need extra caution or should avoid it

Women with recurrent vulvovaginal candidiasis or poorly controlled genitourinary syndrome of menopause may find the infection burden intolerable. Women with severe CKD (eGFR <25 mL/min/1.73 m²) should not use dapagliflozin for glycemic control (though the CKD indication extends lower). Those with a history of lower-limb amputations or peripheral artery disease (a concern flagged more strongly with canagliflozin than dapagliflozin, but worth monitoring) need close vascular assessment. Women who are frail, at high fall risk, or on multiple antihypertensives require very careful volume management before starting this drug.

Women with type 1 diabetes should not take dapagliflozin outside of a clinical trial setting due to DKA risk.

Dosing in Women 65 and Older

The standard dose is 10 mg once daily by mouth, taken in the morning with or without food. No dose adjustment is required based on age alone. Renal function, however, drives the decision:

• eGFR 45 or above: Full glycemic and cardio-renal benefit
• eGFR 25 to 44: Continue for cardio-renal benefit; glycemic efficacy is reduced
• eGFR <25: Not indicated for glycemia; evidence from DAPA-CKD supports continuing for kidney protection down to this threshold
• Dialysis: Contraindicated

Hepatic impairment does not require dose adjustment in mild to moderate disease. Severe hepatic impairment (Child-Pugh C) increases drug exposure and warrants caution.

For older women starting the drug who are also on loop diuretics, a practical approach is to reduce the loop diuretic by 25 to 50% at initiation and reassess kidney function and electrolytes within two to four weeks.

Drug Interactions Relevant to Older Women's Polypharmacy

Women 65 and older are more likely to be on five or more medications. Dapagliflozin has relatively few pharmacokinetic interactions because it is primarily metabolized by UGT1A9, not the CYP450 system.

Relevant interactions to monitor:

• Insulin and sulfonylureas: Dapagliflozin can potentiate hypoglycemia when combined with these agents. Reducing insulin or sulfonylurea dose by 10 to 20% at initiation is often recommended.
• Diuretics: Additive volume depletion. Monitor blood pressure and creatinine.
• NSAIDs: Common in older women for arthritis pain. Chronic NSAID use combined with dapagliflozin increases acute kidney injury risk, particularly during illness.
• Lithium: Used in some older women for mood disorders. Osmotic diuresis from dapagliflozin may affect lithium levels; monitor lithium concentrations after initiation.

The FDA prescribing information does not list major CYP-mediated interactions, which is an advantage in a population managing complex medication regimens.

Monitoring Plan for Older Women on Dapagliflozin

A practical monitoring schedule for a woman 65 or older starting dapagliflozin:

Before starting

• Complete metabolic panel (eGFR, creatinine, electrolytes)
• HbA1c if prescribed for diabetes
• Blood pressure lying and standing (orthostatic assessment)
• Document current diuretic regimen
• DEXA if not done within 2 years (given bone health concerns in postmenopausal women)

At 2 to 4 weeks

• Repeat kidney function and electrolytes
• Assess for volume depletion symptoms (dizziness, dry mouth, decreased urine output)
• Ask about genital symptoms

Every 3 to 6 months

• HbA1c (if diabetes indication)
• eGFR and urine albumin-to-creatinine ratio
• Blood pressure

Annually

• Reassess fracture risk using FRAX score in postmenopausal women
• Review genital health and treat GSM concurrently if present

A Note on Evidence Gaps in Older Women

Women over 65 have been systematically underrepresented in SGLT2 inhibitor trials. The DAPA-CKD trial enrolled approximately 33% women, DAPA-HF enrolled about 23% women, and DECLARE-TIMI 58 enrolled approximately 37% women. Sex-stratified subgroup analyses consistently show directionally similar benefits, but the confidence intervals are wider in women than in men. Age-by-sex interaction data are rarely reported, meaning the specific experience of a woman over 75 is almost entirely extrapolated from younger or predominantly male trial populations. This is an honest limitation that should inform shared decision-making: the cardiovascular and kidney benefits are likely real in older women, but the magnitude and the side-effect profile warrant individualized conversation rather than one-size-fits-all prescribing.

As The Menopause Society's clinical guidance notes on cardiometabolic risk management, "the absence of high-quality data in older women does not equate to absence of benefit, but it does require clinicians to exercise heightened individualization." This framing should guide every conversation about dapagliflozin in a woman 65 and older.